cognitive impairments or abnormalities in subjects with Down's syndrome, wherein said subjects with Down's syndrome have not yet developed amyloid protein-associated plaques in the brain.

13. The use of claim 12, wherein the composition comprises an adjuvant.

14. The use of claim 12 or claim 13 for the treatment and/or alleviation of a disease or impairment as defined in any one of claims 2 to 9.

15. Use of the antigenic peptide as defined in any one of claims 1 to 11 or the composition as defined in any one of claims 12 to 14 in the preparation of a medicament for inducing an immune response against amyloid protein or amyloid-like protein in a subject with Down's syndrome, wherein said subject with Down's syndrome has not yet developed amyloid protein-associated plaques in the brain.